FDA to ban food dye: 10 foods that will look 'different' without food dyes
synthetic food dyes
, including Red 3, due to concerns about potential health risks, particularly cancer in lab rats.
Tired of too many ads? go ad free now
They are also initiating the process to revoke authorization for other synthetic dyes, such as Citrus Red No. 2 and Orange B, and are working with the industry to eliminate six remaining synthetic dyes by the end of 2026.
However, last month, health secretary Robert F. Kennedy Jr. took this initiative a step further and announced that both the Department of Health and Human Services and the FDA will start to roll out a ban on the following synthetic food dyes: Red No.
40, Yellow No. 5, Yellow No. 6, Blue No. 1, Blue No. 2, Green No. 3, Citrus Red 2 and Orange B.
Now, these dyes aren't just found in candy or snacks—some produce, dairy, meat, and other surprising products will be impacted by this new legislation. As the FDA is partnering with NIH to study the impact of food additives on children's health and development, while promoting the use of
natural color additives
as replacements, here are the 10 foods that will 'lose their look' without the color additives!
Cereal:
Cereals such as Lucky Charms and Froot Loops have long been known to contain food dyes like Red No.
40, Blue No. 1, and Yellow No. 5. However, the prevalence of these dyes in many cereals—including Fruity Pebbles, Trix, Fruity Cheerios, Apple Jacks, and Cap'n Crunch's Crunch Berries—might be surprising. Manufacturers will need to explore alternative methods to achieve vibrant colors without using these particular dyes.
Salad Dressing:
Have you ever noticed the classic orange color of Kraft's Creamy French Dressing? This hue is primarily due to the inclusion of Yellow No.
Tired of too many ads? go ad free now
5 and Yellow No. 6, which will be banned. Additionally, Kraft's Classic Catalina dressing contains Red No. 40 and Blue No. 1. Regardless of whether these products contain dyes or not, making salad dressings at home can be a healthier and more flavorful option for enhancing greens.
Sausage:
It may come as a surprise that some hot dogs and sausage casings are dyed using Orange B. While this gives them a distinctly appealing look, consumers can expect a change during the 2027 season when these products will likely be dye-free.
Oranges:
Food dye bans even affect fresh produce. For example, Florida oranges are often dyed with Citrus Red 2 to achieve a vibrant orange peel. This practice is common due to specific climatic or cultural conditions that result in oranges maturing with a green hue. As a result, you might see more green oranges in the market once the dye ban is enacted, but rest assured, they are still ripe and ready to eat.
Canned Vegetables:
Canned vegetables offer a convenient and economical way to boost fiber intake.
However, without food dye Blue No. 1, canned peas may lose some of their bright green color. Despite this change, their nutritional value and taste will remain unchanged.
Preserved Fruit:
Similar to canned vegetables, preserved fruit products like jams, jellies, and marmalades may contain various food dyes. Dried fruits such as papaya, mango, and kiwi often have dyes like Yellow No. 5, Yellow No. 6, or Blue No. 1 added to enhance their appearance.
Yogurt:
Food dyes are not exclusive to children's yogurt; brands like Dannon Light + Fit and Yoplait also utilize dyes such as Red No. 40, Blue No. 1, or Yellow No. 6 for color enhancement. Consumers can expect a more subdued color in yogurt varieties like strawberry Yoplait Light or Key lime Light + Fit Greek yogurt in the future.
Drink Mixes and Electrolyte Drinks:
Many popular drink brands, including Gatorade, Powerade, and Pedialyte, include dyes like Red No.
40 and Blue No. 1 in their ingredients. Additionally, powdered drink mixes like Sunkist, Country Time, 4C, Kool-Aid, and Crystal Light rely on food dyes for visual appeal. Be prepared for potential differences in appearance when they come to market without these dyes; you may need to stir or shake them more thoroughly.
Seasonings:
Certain seasoning mixes, such as Great Value's Lemon & Pepper Seasoning, derive their color from artificial dyes.
As a result, the colors in meals may appear more muted post-ban. Incorporating fresh ingredients, such as lemon slices, can help enhance the color of dishes like Grilled Lemon-Pepper Salmon in Foil.
Condiments and Sauces:
In addition to salad dressings, various condiments in your refrigerator will also be impacted by the food dye ban. Products like Great Value's Cocktail Sauce and Vlasic's Sweet Relish currently contain dyes such as Red No.
40 and Yellow No. 5, which will be removed in the near future.
Common food dye can trigger inflammatory bowel diseases: Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
10 hours ago
- The Hindu
Weight regain begins 8 weeks after stopping anti-obesity drugs, says study
A review of data from clinical trials of weight-loss drugs has concluded that weight regain begins about eight weeks after stopping these medications, and continues up to 20 weeks, before stabilising at about 26 weeks. The paper 'Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications' published in BMC Medicine, an open access, transparent peer-reviewed general medical journal, also observed that at 52 weeks, the subjects of the trial still weighed less than they did before starting medication, but the weight loss was reduced compared to when they were actively taking the drugs. 11 clinical trials The researchers Han Wu et al, from the Department of Endocrinology and Metabolism, Peking University People's Hospital, China, analysed data from 11 clinical trials with 1,573 people taking anti-obesity medication. These medications included: GLP-1 receptor agonists (such as semaglutide, liraglutide), orlistat, naltrexone-bupropion, and phentermine-topiramate. Randomised controlled trials of anti-obesity medications conducted in the population for at least four weeks and followed up for four or more weeks after discontinuation were included. The review sought to examine the post-trial period when the drugs stop, estimate what happens to the weight of these patients, how much weight is regained, how soon do they begin to regain weight and the impact of lifestyle factors on weight. The researchers observed that people who lost more weight during treatment were more likely to regain weight, even if they continued lifestyle interventions (including diet and exercise). Those who started with a lower body mass index (BMI), meaning they were less overweight, showed more weight regain after stopping than those with higher BMI. Interestingly, people taking GLP-1-related drugs experienced more weight regain after stopping than those on other drugs, they reported in the paper. Different weight regain was observed in subjects with different characteristics, the researchers said, adding that studies with a longer follow-up duration are required to further investigate the potential factors associated with weight change after discontinuation of treatment. Hope to many 'This is an interesting study with robust meta analyses, but similar results have been shown in many other trials too,' says Dr. Nanditha, consultant diabetologist, Dr. A. Ramachandran's Diabetes Hospitals, Chennai. 'Any intervention, either when you step down or discontinue, will result in weight gain, even if it is lifestyle modifications.' However, it is important to see the usefulness of these drugs in the context of the obesity epidemic. Obesity, originally, was looked upon as a risk factor, but is now considered a disease by itself. 'Earlier, we did not have many tools to treat it, now these drugs are providing hope to people who can lose weight without surgery. What is clear is that the regain will not take you back to the baseline weight, so while expensive, these drugs should be considered an investment, because the benefits go beyond weight loss,' she said. It may be remembered that another study, published recently in the journal Obesity, showed that semaglutide and tirzepatide — injectable GLP-1 drugs for obesity — produce lower weight loss in a real-world setting, as compared to during the clinical trial, because patients discontinue treatment or use lower maintenance dosages.
Time of India
14 hours ago
- Time of India
Sarepta shares fall 7% after gene therapy maker pauses Elevidys shipments in US
Shares of Sarepta Therapeutics fell nearly 7% on Tuesday after the company agreed to comply with the U.S. health regulator's request to pause all shipments of its gene therapy Elevidys in the United States. The U.S. Food and Drug Administration on Friday asked Sarepta to voluntarily halt shipments of the gene therapy, but the company refused to do so and said it would continue making the treatment available to ambulatory patients. Explore courses from Top Institutes in Please select course: Select a Course Category Product Management Technology Degree Others Management Artificial Intelligence Public Policy MCA others PGDM healthcare Design Thinking Operations Management Finance Data Analytics Project Management MBA CXO Digital Marketing Leadership Data Science Data Science Skills you'll gain: Product Strategy & Competitive Advantage Tactics Product Development Processes & Market Orientations Product Analytics & Data-Driven Decision Making Agile Development, Design Thinking, & Product Leadership Duration: 40 Weeks IIM Kozhikode Professional Certificate in Product Management Starts on Jun 26, 2024 Get Details Skills you'll gain: Product Strategy & Roadmapping User-Centric Product Design Agile Product Development Market Analysis & Product Launch Duration: 24 Weeks Indian School of Business Professional Certificate in Product Management Starts on Jun 26, 2024 Get Details Skills you'll gain: Creating Effective Product Roadmap User Research & Translating it to Product Design Key Metrics via Product Analytics Hand-On Projects Using Cutting Edge Tools Duration: 12 Weeks Indian School of Business ISB Product Management Starts on May 14, 2024 Get Details by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Trekking pants for mountain sports and adventure travel Trek Kit India Shop Now But Sarepta has now voluntarily and temporarily paused all shipments of the therapy, effective end of Tuesday. The company said the decision would allow it to respond to requests from the FDA and maintain a positive relationship with the agency. "Though Sarepta claims its pause in shipments was voluntary, we think the company moved preemptively - bracing for an inevitable FDA mandate to pull the drug," said H.C. Wainwright analyst Mitchell Kapoor. Shares of Sarepta fell 6.9% to $12.40 in early trading on Tuesday. Live Events "Sarepta's decision to comply was a capitulation after recognizing that the fight with the FDA was not winnable and that the agency would have strong-armed Sarepta into removing Elevidys with a formal demand," Kapoor added. Investor concerns regarding the use of the company's treatments have been heightened after the company on Friday disclosed that another patient who had received its experimental gene therapy died from acute liver failure , marking the third death this year. The company's shares have plummeted 89% so far this year. On Monday, Children's Hospital Los Angeles said it had paused usage of Elevidys in all patients with muscular dystrophy . The FDA's initial request had likely heightened the pressure on physicians to pause treatments, which could also have been a driving factor in Sarepta's decision, William Blair analyst Sami Corwin said.
The Hindu
14 hours ago
- The Hindu
Alzheimer's disease: Researchers find two cancer drugs reverse damaged gene behaviour in mice
A study that compared gene behaviour in Alzheimer's disease with that caused by 1,300 drugs approved for use in the US has found that a combination of two cancer drugs could slow the neurodegenerative disease in mice, indicating a promise in reversing symptoms in humans. Alzheimer's disease is an ageing-related disorder in which cognitive function steadily declines, affecting speech and memory, and eventually can interfere with everyday activities. Scientists at the University of California, San Francisco, and Gladstone Institutes in the US first saw how gene behaviour was affected in Alzheimer's disease in a single brain cell. The researchers then looked at 1,300 drugs approved by the US Food and Drug Administration (FDA) and which of them reversed the damage. The next stage of the study, published in the journal 'Cell', analysed electronic medical records of about 1.4 million patients and found that patients who took some of these drugs for treating conditions other than Alzheimer's disease were less likely to get the ageing-related neurological disorder. Testing the top two drug candidates -- 'letrozole' and 'irinotecan', both of which are cancer medications -- in a mouse model having Alzheimer's disease, the researchers found that brain degeneration was reduced and a restored ability to remember. Letrozole is usually prescribed for treating breast cancer, and irinotecan for colon and lung cancer. The combined effects of two drugs were found to reverse damaged gene behaviour in neurons and glia (a type of brain cells that surround and support neurons). Further, toxic clumps of proteins and brain degeneration -- hallmark features of Alzheimer's -- were found to be reduced and memory restored, the researchers said. The team added that out of 1,300 drugs, 86 reversed gene behaviour changes in one type of brain cell and 25 reversed them in other types. However, only 10 had been approved for use in humans by the FDA. "Thanks to all these existing data sources, we went from 1,300 drugs, to 86, to 10, to just five," said lead author Yaqiao Li, a postdoctoral scholar at Gladstone Institutes. "Alzheimer's disease comes with complex changes to the brain which has made it tough to study and treat, but our computational tools opened up the possibility of tackling the complexity directly," said co-senior author Marina Sirota, professor of paediatrics and an interim director at the University of California. Co-senior author Yadong Huang, director of the center for translational advancement at Gladstone Institutes, said, "Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health." "This makes it very challenging for drug development -- which traditionally produces one drug for a single gene or protein that drives disease," Huang said. The electronic medical records analysed in the study came from the University of California's Health Data Warehouse, which includes anonymised health information on 1.4 million people over the age of 65.
